Clinical & Scientific

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

A Utah biotech reports promising results for a novel mRNA therapy that makes cancer cells look like measles, setting the stage for crucial animal trials.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

A new alliance between Guardant Health and Trial Library uses AI and massive datasets to dismantle barriers, connecting more patients to vital cancer research.

A new contract for its explainable AI in a pivotal Phase 3 trial shows NetraMark is helping Big Pharma de-risk its most expensive R&D phase.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

With a massive $550M capital infusion, Immunovant is poised to accelerate its novel Graves' Disease therapy, IMVT-1402, toward commercial launch.

A French cancer institute is the first in Europe to deploy a new radiotherapy system that promises not just better accuracy, but a more humane patient journey.

Eli Lilly's takeover of Adverum signals a major push into ocular gene therapy. Can a one-time injection for vision loss disrupt a multi-billion dollar market?

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.